Home / Industry Corner: Cloud Pharmaceuticals

Industry Corner: Cloud Pharmaceuticals

Cloud Pharmaceuticals, a cloud-based drug design and development company, is interested in potential collaborations around myotonic dystrophy targets.

Cloud Pharmaceuticals designs targeted therapeutics using cloud-based high performance computing platforms and delivers novel molecular designs of ligands to druggable targets.

The company's Quantum Molecular Design process has three components:

  • Produce virtual chemical space and search for novel drug scaffolds 
  • Accurate prediction of ligands binding to the protein active site 
  • Expert system to choose the molecules with the highest probability of becoming drugs 

An article describing their technology has just been published (geared toward non-experts).

Contact Chief Science Officer Dr. Shahar Keinan at skeinan@cloudpharmaceuticals.com.

Are you currently doing DM work or seeking DM-related collaborations? Please contact MDF’s Chief Science Officer, Dr. Sharon Hesterlee at sharon.hesterlee@myotonic.org.

Partners

University of Florida Logo 100px.png Houston Methodist Logo 100px.png University of Iowa 100px.png University of Kansas Logo 100px.png National Institute of Health 100px.png Ohio State University Logo 100px.png University of Rochester 100px.png Stanford University Logo 100px.png University of Utah Logo 100px.png Virginia Commonwealth University Logo 100px.png Wyck Logo 150px.png

© Myotonic Dystrophy Foundation. All rights reserved.